EMA Application withdrawn: Miplyffa (arimoclomol citrate) — Orphazyme A/S

View source ↗

Summary

The EMA has withdrawn the application for Miplyffa (arimoclomol citrate) by Orphazyme A/S for Niemann-Pick Disease Type C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Niemann-pick Disease Type

Drugs mentioned

• MIPLYFFA (ARIMOCLOMOL CITRATE)

Snippet

Status: Application withdrawn. Therapeutic area: Niemann-Pick Disease, Type C. MAH: Orphazyme A/S. Orphan medicine